Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development

Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice

(2020) Sharmilla Devi Jayasingam et al.   Frontiers in Oncology

Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix

(2020) Scott Caroen et al.   Expert Opinion on Drug Delivery

BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases

(2020) Michelle M. Kim et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase I pilot study of RRx-001 + nivolumab in patients with traditionally non-checkpoint inhibitor-responsive cancers (PRIMETIME).

(2020) Corey Carter et al.   JOURNAL OF CLINICAL ONCOLOGY

Just eat it: A review of CD47 and SIRP-α antagonism

(2020) Bryan Oronsky et al.   SEMINARS IN ONCOLOGY

RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages

(2019) Pedro Cabrales   Translational Oncology

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer

(2019) Daniel Morgensztern et al.   BRITISH JOURNAL OF CANCER

REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer

(2019) Bryan Oronsky et al.   Future Oncology

Nitrite may serve as a combination partner and a biomarker for the anti-cancer activity of RRx-001

(2019) Selma Cirrik et al.   BIORHEOLOGY

Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001

(2018) Bryan Oronsky et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma

(2018) Magdalena Jarosz-Biej et al.   PLoS One

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis

(2018) Bryan Oronsky et al.   Translational Oncology

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells

(2018) Bryan Oronsky et al.   Oncotarget

Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects

(2017) Zhangjian Huang et al.   JOURNAL OF MEDICINAL CHEMISTRY

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury

(2017) Pedro Cabrales et al.   Expert Review of Hematology

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors

(2017) Natarajan Raghunand et al.   Oncotarget

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry

(2017) Hongjuan Zhao et al.   Clinical Epigenetics

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas

(2017) Bryan Oronsky et al.   NEOPLASIA

Abstract 2165: Enhanced uptake and accumulation of temozolomide and irinotecan in orthotopically-implanted gliomas by vascular priming with RRx-001

(2016) Pedro Cabrales et al.   CANCER RESEARCH

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

(2016) Bryan Oronsky et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

RRx-001, A novel dinitroazetidine radiosensitizer

(2016) Bryan Oronsky et al.   INVESTIGATIONAL NEW DRUGS

A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells

(2016) D Sharma Das et al.   LEUKEMIA

Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation

(2016) Marcel H. Fens et al.   MEDICAL ONCOLOGY

A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?

(2016) Pedro Cabrales et al.   MEDICAL ONCOLOGY

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases

(2016) Michelle M. Kim et al.   NEURO-ONCOLOGY

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial

(2016) Michelle M. Kim et al.   Translational Oncology

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy

(2016) Bryan Oronsky et al.   Oncotarget

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors

(2016) Bryan Oronsky et al.   Clinical Epigenetics

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study

(2015) Tony Reid et al.   LANCET ONCOLOGY

Abstract C181: RRx-001 combined with anti-PD-L1 antibody increases the complete response rate in a preclinical myeloma model

(2015) Susan J. Knox et al.   MOLECULAR CANCER THERAPEUTICS

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001

(2015) Shoucheng Ning et al.   Oncotarget

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent

(2015) Jan Scicinski et al.   Redox Biology

Redox regulation of genome stability by effects on gene expression, epigenetic pathways and DNA damage/repair

(2015) Yuliya Mikhed et al.   Redox Biology

Abstract 2068: RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI In preclinical tumor models

(2015) Natarajan Raghunand et al.   CANCER RESEARCH

The Capacity of Red Blood Cells to Reduce Nitrite Determines Nitric Oxide Generation under Hypoxic Conditions

(2014) Marcel H. Fens et al.   PLoS One

Six Degrees of Separation: The Oxygen Effect in the Development of Radiosensitizers

(2014) Bryan T. Oronsky et al.   Translational Oncology

Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review

(2014) Bryan T. Oronsky et al.   Translational Oncology

Beyond Antiangiogenesis: Vascular Modulation as an Anticancer Therapy—A Review

(2014) Bryan T. Oronsky et al.   Translational Oncology

Development of methods for the bioanalysis of RRx-001 and metabolites

(2014) Jan Scicinski et al.   Bioanalysis

Abstract 676: Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials

(2012) Shoucheng Ning et al.   CANCER RESEARCH

Abstract 4371: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors

(2012) Jan Scicinski et al.   CANCER RESEARCH

Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials

(2012) S. Ning et al.   CANCER RESEARCH

The Effects of Temperature and pH on Secondary Structure and Antioxidant Activity of Crocodylus siamensis Hemoglobin

(2011) Jinda Jandaruang et al.   PROTEIN JOURNAL

Isolation and characterisation of crocosin, an antibacterial compound from crocodile (Crocodylus siamensis) plasma

(2010) Sutthidech PREECHARRAM et al.   ANIMAL SCIENCE JOURNAL

Can inhibition of angiogenesis and stimulation of immune response be combined into a more effective antitumor therapy?

(2010) Stanisław Szala et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Mimetics of Hormetic Agents: Stress-Resistance Triggers

(2010) Joan Smith Sonneborn   Dose-Response

A Perspective on the Scientific, Philosophical, and Policy Dimensions of Hormesis

(2009) George R. Hoffmann   Dose-Response